This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (13)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Thrombolysis  • Venous Thromboembolism  • Cardiovascular System  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2006;295:743-744.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Atlanta—While blood clots are essential to prevent excessive bleeding from wounds, they can wreak havoc if they form abnormally and obstruct the flow of blood throughout the body, as can happen following some surgeries. Current anticoagulant therapies for such complications, while effective, have many limitations and adverse effects.

Researchers are thus seeking better alternatives for the millions of individuals who are prescribed anticoagulant drugs each year. Such efforts are beginning to bear fruit, according to researchers at the annual meeting of the American Society of Hematology here in December who presented promising findings about two novel oral anticoagulants for treating and preventing thromboembolic events following orthopedic surgery.

Angiograms showing two views of a leg show a clot (white) that is restricting blood flow. Anticoagulants are often given after orthopedic surgery to prevent deep vein thromboses. (Photo credit: St Bartholomew's Hospital/www.sciencesource.com)

CURRENT ANTICOAGULANTS

Thromboembolic events, such as . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Inhibitors of Factor VIIa/Tissue Factor
Shirk and Vlasuk
Arterioscler. Thromb. Vasc. Bio. 2007;27:1895-1900.
ABSTRACT | FULL TEXT